#78
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this review to understand the neurobiological mechanisms through which cannabis affects mental health conditions, enabling informed risk-benefit discussions with patients seeking or using cannabis for psychiatric symptoms. The endocannabinoid system’s role in emotional regulation means cannabis use carries potential benefits for some conditions but documented risks including psychosis, anxiety exacerbation, and cognitive effects that require careful patient screening and monitoring. Evidence-based knowledge of these mechanisms helps clinicians provide appropriate counseling, identify vulnerable populations, and support safer use patterns or recommend alternatives for patients with mental health conditions.
This review examines the endocannabinoid system’s role in mental health and the evidence for cannabis use in psychiatric conditions. The endocannabinoid system, composed of receptors, endogenous cannabinoids, and their metabolizing enzymes, plays a fundamental role in mood regulation, anxiety processing, and stress response, making it a theoretically attractive target for mental health treatment. However, current clinical evidence presents a mixed picture: while some patients report symptom relief for anxiety and insomnia, robust randomized controlled trials demonstrating efficacy and safety in psychiatric populations remain limited, and cannabis use is associated with increased risks of psychosis, cognitive impairment, and cannabis use disorder, particularly in vulnerable populations and with high-THC products. The neurobiological complexity of the endocannabinoid system means that whole-plant cannabis effects do not reliably parallel laboratory findings, and standardization across products remains inadequate for clinical decision-making. Clinicians should counsel patients with mental health conditions that evidence for cannabis efficacy in psychiatry is insufficient to recommend it as a first-line treatment, and that the substantial risks, particularly for psychosis and dependence, likely outweigh potential benefits for most psychiatric patients.
“The endocannabinoid system’s role in mood regulation is real, but we’ve spent two decades chasing therapeutic potential while ignoring the equally real risk that regular cannabis use, particularly in adolescents and those with genetic vulnerability to psychosis, can destabilize mental health in ways we’re still working to predict clinically. What I tell my patients is that we need biomarkers and pharmacogenomic data before we can responsibly recommend cannabis for psychiatric symptoms, because right now we’re largely guessing about who benefits and who gets harmed.”
💊 While cannabis’s effects on the endocannabinoid system are increasingly understood at the molecular level, clinical evidence for its mental health applications remains mixed and inadequately controlled for confounding variables such as baseline psychiatric severity, concurrent medication use, and frequency/potency of cannabis exposure. The distinction between cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)—which may have opposing effects on anxiety and psychosis risk—is often lost in public discourse and patient self-medication practices, yet most available cannabis products contain variable ratios of these compounds. Additionally, longitudinal studies suggest dose-dependent associations between regular cannabis use and adverse mental health outcomes, particularly in adolescents and those with genetic vulnerability to psychotic disorders, which complicates counseling around “therapeutic” use. Clinicians should maintain a detailed substance use history that specifically probes cannabis frequency, product type, and THC content, screen systemat
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: